How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about histamine dihydrochloride with interleukin‑2

Marketing authorisation indication

2.1

Histamine dihydrochloride (Brancaster Pharma) is indicated for 'adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin‑2 (IL-2). The efficacy of Histamine dihydrochloride 0.5 mg/0.5 mL solution for injection has not been fully demonstrated in patients older than age 60'.

Dosage in the marketing authorisation

Price

2.3

Histamine dihydrochloride costs £1,200 for 14 vials (equivalent to 1 week of treatment; company submission).

2.4

Interleukin‑2 (aldesleukin) costs £636 per 18 million unit vial (BNF online accessed March 2026).

2.5

Costs may vary in different settings because of negotiated procurement discounts.

Sustainability

2.6

Information on the Carbon Reduction Plan for UK carbon emissions for Brancaster Pharma will be included here when guidance is published.